REL-P11 is a proprietary, low-dose, modified-release psilocybin formulation. Single-Ascending Dosing (SAD) study to evaluate safety and pharmacokinetics in obese and normal weight ...

People suffering from major depressive disorder (MDD) and treatment-resistant depression (TRD) often face challenging ...

Twelve Step programs like Alcoholics Anonymous, Narcotics Anonymous and Cocaine Anonymous are free, self-supporting and do ...

The clerk said she has been diagnosed with PTSD, major depressive disorder and generalized anxiety disorder, and is no longer the outgoing, “larger than life” individual she once was. “I can’t believe ...

Neumora Therapeutics, Inc. (NMRA – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Neuronetics ( (STIM) ) has released its Q3 earnings. Here is a breakdown of the information Neuronetics presented to its investors.

Cybin (Cboe CA:CYBN) has begun its Phase 3 pivotal program, PARADIGM, to evaluate the efficacy and safety of CYB003 as an ...

UB neuroscientists have identified the binding site of low-dose ketamine, providing critical insight into how the medication ...

Tiara Gray was diagnosed with 3 mental conditions, including bordeline personality disorder. Yet the Navy kept her in a high-pressure job.

Psilocybin-assisted therapy could potentially benefit up to 5.6 million Americans with major depressive disorder or treatment ...